Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

Novartis' Entresto is nothing more than an attempt

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
debunker1 Member Profile
 
Followed By 0
Posts 29
Boards Moderated 0
Alias Born 08/16/17
160x600 placeholder
Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece Dow Jones News - 6/14/2019 8:04:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2019 1:32:53 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/7/2019 6:38:58 AM
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options Business Wire - 6/6/2019 5:15:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 6:22:29 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/3/2019 11:12:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 2:05:17 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/24/2019 6:27:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2019 9:58:51 AM
Thermo Fisher to Buy Ireland API Plant From GlaxoSmithKline Dow Jones News - 5/16/2019 6:40:00 AM
Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK PR Newswire (US) - 5/16/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2019 4:35:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2019 4:06:10 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2019 2:03:27 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/2/2019 4:16:42 PM
GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial Dow Jones News - 5/2/2019 12:59:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/2/2019 12:49:25 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 1:38:47 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 1:19:50 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 11:27:14 AM
GlaxoSmithKline Reports Growing Turnover and Profit in 1Q, Beating Market Expectations Dow Jones News - 5/1/2019 7:58:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/29/2019 8:28:21 AM
FDA Approves GlaxoSmithKline's Treatment for Pediatric Patients with Lupus Dow Jones News - 4/26/2019 4:31:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/26/2019 1:50:27 PM
GlaxoSmithKline Subsidiary Gets Positive Opinion for HIV Drug Dow Jones News - 4/26/2019 12:00:00 PM
debunker1   Wednesday, 06/13/18 07:33:12 AM
Re: None
Post # of 137 
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist